Navigation Links
Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Date:2/10/2010

s in the EU and US, the Company plans to design and conduct an exploratory Phase 2 single-arm study in adult patients with relapsed/refractory CLL. The Company currently plans to initiate patient enrollment by the end of 2010.

Webcast replay

A replay of the Company's R&D Day webcast, along with presentation slides, is available through a link on Micromet's web site at www.micromet-inc.com.  

About Blinatumomab

Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas. Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study. Blinatumomab was generally well-tolerated by patients in the Phase 2 study.  The most frequently reported grade 3/4 adverse event was lymphopenia.  All other adverse events were infrequent and transient in nature.  Micromet received orphan drug designation from the EMEA for blinatumomab for the treatment of ALL in August 2009.

About Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia (ALL) is a cancer of the blood and bone marrow that afflicts 5,760 patients in the U.S. annually.(1)  ALL is the most common type of cancer in children. The average five-year survival rate for adult ALL patients after 1st relapse is 7%.  The presence of minimal residual disease, or MRD, is a recognized negative prognostic factor for patients with ALL.  According to published results(2), MRD-negative patients incurred a 6% ri
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
2. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
3. Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
7. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
8. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
9. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
10. Micromet Key Events for 2009
11. Micromet Expands Committed Equity Financing Facility to $75 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Israël, 4 mars 2015 /PRNewswire/ ... (« RedHill » ou la « Société »), une ... sur les spécialités pharmaceutiques administrés ... stade clinique avancé pour les ... notamment les cancers gastro-intestinaux, a ...
(Date:3/4/2015)... 2015 Perrigo Company plc (NYSE: PRGO ... Joseph C. Papa will present at the 2015 ... 11, 2015 at the Loews Miami Beach Hotel in ... presentation webcast at http://perrigo.investorroom.com/events-webcasts . From its ... Perrigo Company plc, headquartered in Ireland , ...
(Date:3/4/2015)... N.J. , March 4, 2015   ... company developing innovative medicines for serious women,s health ... clinical program demonstrating that its lead product candidate, ... predictable pharmacokinetics (PK), and that contraceptive efficacy for ... SYM-1219 administration. These results will be ...
Breaking Medicine Technology:RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 2RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 3RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 4RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 5Perrigo Company To Present At The 2015 Barclays Global Healthcare Conference 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5
... and Drug Administration (FDA) has recently issued safety alerts about ... ) birth control pills that may ... diabetes medicines that carry new restrictions dietary supplements packaged ... These and other alerts were prompted by ...
... Texas, June 28, 2011 Pharmacy Choice and ... local businesses and pharmacists across the nation and ... care – applauds the Texas Legislature for the ... critical amendments that provide necessary protections for Texans ...
Cached Medicine Technology:Pharmacy Choice and Access Now Coalition Applauds Passage of Senate Bill 7 During Texas Legislature's Special Session 2
(Date:3/4/2015)... 04, 2015 The Global Liquefied ... in 2014 and is estimated to grow to ... 4.0% from 2014 to 2019. , Browse through ... for an analysis of industry trends, segments & ... liquefied petroleum gas market is classified into source, ...
(Date:3/4/2015)... Organic Valley, the nation’s largest cooperative of organic ... campaign to Save the Bros, http://savethebros.com/ with its ... to Bros everywhere. To date, the video has earned ... video was named Adweek’s best commercial of the week on ... among other media outlets. , “We are pleased to ...
(Date:3/4/2015)... USA (PRWEB) March 04, 2015 Columbus is ... a steady prevalence of cocaine addiction, and suffers from ... WKYC on Feb. 27th, the DEA revealed that Kratom ... as a herbal tea; the newly introduced herb from Southeast ... heroin in heightened doses. WKYC notes kratom foments symptoms similar ...
(Date:3/4/2015)... Sonoma, CA (PRWEB) March 04, 2015 ... which supports American military service members during and after ... for a Cause,” will increase awareness through advertising, social ... raise funds for the patriotic organization through a special ... Cabernet Sauvignon wines from March through May 2015. ...
(Date:3/4/2015)... New Port Richey, FL (PRWEB) March 04, 2015 ... Novus Medical Detox cut the ribbon on their new facility ... West Pasco Chamber of Commerce. The new facility will allow ... mission of helping end the prescription drug abuse epidemic through ... the current reality of drug addiction in the United States, ...
Breaking Medicine News(10 mins):Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 2Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3
... conference,focusing on the future of healthcare will convene ... Summit will present an opportunity for leaders from,around ... and future seismic,"tremors" in the healthcare industry in ... make the industry virtually unrecognizable in,the coming years., ...
... Corporation (Nasdaq: HLTH ) and its approximately 83% owned ... they will release,their respective financial results for the three months ... May 6, 2008. The Companies,will host a conference call at ... Investors can access the call via webcast at http://www.hlth.com ...
... Medicine Led by Simmons School for Health,Studies, BOSTON, ... (Dietary Approaches to Stop Hypertension), which is high in,fruits ... risk of coronary heart disease and stroke, according to ... Internal Medicine., The study indicates for the first ...
... amount had almost half the risk of needing to start ... with naturally high levels of the antioxidant urate in their ... than those with lower levels do, a new report says. ... Archives of Neurology , support early laboratory studies about ...
... DASH diet cuts cardiovascular risk, studies find , , MONDAY, ... additional benefits of widely used measures aimed at preventing ... the DASH diet for blood pressure control lowers the ... , The statin study wasn,t intended to measure the ...
... Americas Baby Boomer generation, arthritis is a growing ... common joint disease currently afflicts over 20 million ... aggravate matters, arthritis is also prevalent among the ... adult population. Fortunately, treating the pain and disability ...
Cached Medicine News:Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Risk of Women's Heart Attack or Stroke Appears to Be Lowered by 'DASH' Diet 2Health News:Elevated Urate Levels May Slow Parkinson's in Men 2Health News:New Benefits From Old Heart Measures 2Health News:New Benefits From Old Heart Measures 3Health News:Study shows increase of hip and knee replacements in the US 2Health News:Study shows increase of hip and knee replacements in the US 3
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
Sonix CEP provides Emergency Medicine practitioners with high performance imaging in a compact, portable system that boots up in seconds and runs on rechargeable battery up to 30 minutes so it's alwa...
MPatch® is a topical adhesive wound dressing for the local management and control of bleeding from vascular access sites and percutaneous catheters....
O-arm combines the best features of a traditional c-arm with an intra-operative 3D scannerfor unparalleled surgical imaging....
Medicine Products: